NEW YORK — Owlstone Medical, a UK-based developer of breath-based diagnostics, said on Wednesday that it has closed a $27 million Series E financing round.

The UK-based firm has issued five Class II recalls for its RX-series analyzers since 2018 for issues related to reagent carryover between subsequent tests.

The test detects HIV-1/2 antibodies in finger prick samples and is intended for use by healthcare professionals in any healthcare setting.

The report also indicates that while PAMA has cut spending on routine tests, overall lab spending has risen as genetic testing continues to grow.

The firm said preliminary core Q4 2024 revenues are expected to be flat, exceeding prior expectations, while its China business has stabilized and will recover.

The recent clearance and a previous clearance together allow the use of Paige's FullFocus digital pathology image viewing software with scanners by Philips, Leica, and Hamamatsu.

The company said it expects Q4 2024 revenues of roughly $34.9 million, up from $31.5 million in Q4 2023 and above the consensus Wall Street estimate of $34.4 million.

NEW YORK – Pathology software developer Aiosyn said recently that it has gained CE marking for an algorithm that is used for mitotic figure counting in breast cancer diagnostics. The Nijmegen, ...

Last week, readers were most interested in a story about the progress made by test developers toward commercializing rapid tests for sepsis.

The rapid spinning disk-based immunoassay technology will enhance BioMérieux's offering at the point of care, the firm said.

Rounding out the other four largest financing rounds in 2024 are proteomics company Alamar Biosciences' $128 million Series C ...

Following OraSure's November 2024 lawsuit accusing NowDx of misappropriating trade secrets, NowDx has countersued OraSure over similar allegations.